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Galectin-1 is essential in tumor angiogenesis and is a target for anti-angiogenesis therapy.
Victor 
Introduction
An adequate vasculature is a prerequisite for tumors to grow, and the need for neovessel formation (or angiogenesis) provides a target for treatment of cancer (1) . Endothelial cells (EC) that line the tumor vasculature are particularly suitable target cells for therapeutic approaches since they are easily accessible to agents delivered via the blood (2) . However, to affect only tumor vasculature, specific targets on angiogenically active EC are essential. To date, only a few targets of tumor vasculature have been identified (3) .
We recently developed the specific angiostatic peptide anginex that inhibits tumor growth through specific inhibition of angiogenesis (4) (5) (6) . Although a broad profile of activities of anginex is known, such as prevention of EC adhesion and induction of apoptosis, the molecular target on tumor EC was never identified. In a receptor finding study using a yeast two-hybrid screening approach, we identified galectin-1 as a target protein of anginex.
Galectin-1 belongs to a family of carbohydrate binding proteins that share a conserved carbohydrate recognition domain (CRD) of approximately 130 amino acids (7) (8) (9) . Over a dozen mammalian galectins have been described (10, 11) and members of this family are expressed in a wide range of species, suggesting an important role for galectins in basic cellular mechanisms.
Galectins can be secreted, and depending on the cell type or state of differentiation, they have been found in the nucleus, in the cytoplasm, or in the extracellular matrix. It has been proposed that galectin-1 mediates cell adhesion and migration (12) , and is involved in several processes including proliferation (13) , apoptosis (14) , and even mRNA splicing (15) . The role of galectin-1 in EC function or in vascular biology has not been extensively studied.
Here, we describe the function of galectin-1 in the angiogenesis. We provide direct functional evidence that galectin-1 is required for tumor angiogenesis and for outgrowth of tumors.
Furthermore, we show that galectin-1 is the target for the potent angiogenesis inhibitor anginex, thus establishing galectin-1 as an important target for anti-cancer therapy.
Results
Galectin-1 binds the angiostatic peptide anginex.
The goal of the present study was to identify the receptor of anginex, an angiogenesis inhibitor which has previously been shown to specifically target tumor endothelial cells (EC) (5) .
Immunohistochemistry revealed vesicular uptake of anginex by EC within 2 hours (Fig. 1A) .
Electron microscopy showed anginex located at the membrane of intracellular vesicles, suggesting receptor-mediated uptake (Fig. 1B) . To identify this receptor, yeast two-hybrid (Y2H)
analysis was performed. To that end, the recently described artificial anginex gene (16) Galectin-1 is overexpressed in tumor EC; a crucial role in EC proliferation and migration.
To determine the role of gal-1 in tumor EC biology, we first analyzed gal-1 expression in human tumor blood vessels by immunohistochemistry. While gal-1 is only weakly expressed in EC of normal tissue (colon is shown: Figure 1C , left panels), a strong expression was found in EC of human colon carcinoma ( Figure 1C , middle panels) and breast carcinoma (not shown), especially in EC that stained positive for the proliferation marker Ki67. Similar results were observed for a sarcoma type of tumor (Ewing sarcoma) in which the gal-1 staining was almost exclusively observed in vessels ( Figure 1C, right panels) . These data demonstrate that the amount of gal-1 protein is upregulated in angiogenically active EC. Indeed, growth factor activation of freshly isolated human umbilical vein EC resulted in a significant increase in gal-1 mRNA expression and a concomitant >10-fold induction of gal-1 protein expression ( Figure   1D ). Furthermore, treatment of activated EC with a gal-1 specific antisense oligodeoxynucleotide (ODN) resulted in inhibition of EC proliferation, while a random ODN had no effect ( Figure   1E ). Next to EC proliferation, EC migration was also inhibited by treatment with either the gal-1 specific ODN ( Figure 1F ) or the rabbit polyclonal anti-gal-1 antibody ( Figure 1G ). These data strongly suggest a role for gal-1 in EC biology.
Galectin-1 is required for coordinated angiogenesis in vivo.
The role of gal-1 in angiogenesis in vivo was first studied in the chick chorioallantoic membrane (17) . Recently, 3 prototype galectins were described in zebrafish (Lgals1-L1/L2/L3) of which Lgals1-L2 was found to preferentially bind N-acetyllactosamine, similar to human gal-1 (18) . Since Lgals1-L1 is not expressed during embryogenesis (18) we only studied the role of the other two prototype galectins in vascular 
Galectin-1 facilitates tumor progression through angiogenesis.
The presented results urged us to study the role of gal-1 by analyzing tumor angiogenesis in the gal-1 null mice (19) . To compare tumor growth in the presence or absence of gal-1, wild type Figure 4C ). In addition, parameters of vessel architecture were decreased (Suppl. Table   2 ). Since gal-1 has been shown to mediate apoptosis in activated T cells, which could contribute positively to tumor growth (20), we also quantified the amount of peripheral blood leukocytes, and the presence of CD45 + and CD8 + cells in the tumors. There was no significant difference in these parameters between gal-1 +/+ and gal-1 -/-animals (Suppl. Fig. 3 ) which strongly suggests that, in this particular model, impaired tumor progression in gal-1 null mice largely results from decreased angiogenesis.
Galectin-1 is a target protein for angiostatic therapy.
Because gal-1 was initially identified as a receptor for the angiostatic peptide anginex, we also analyzed the effect of anginex treatment in wild type and gal-1 null mice. In wild-type animals, anginex significantly inhibited tumor growth by approximately 70% ( Figure 4D ) and vessel density by approximately 55% (Figure 4E ), which is comparable with previous observations for anginex in other tumor models (5, 21) . In gal-1 -/-mice, treatment with anginex had no effect on tumor growth ( Figure 4F ). In addition, anginex treatment did not significantly affect the number of infiltrating CD45 + or CD8 + cells in the tumors of both the wild type and null mice (Suppl. Fig.   4 ). These data demonstrate that gal-1 mediates the angiostatic activity of anginex and that gal-1 can serve as a target for angiostatic therapy.
Discussion
The current study is the first to demonstrate that gal-1 is important in tumor angiogenesis and that targeting of gal-1 can be an efficient angiostatic therapeutic strategy. Previous studies have shown that gal-1 is key in two mainstays of cancer. Firstly, gal-1 supports metastasis formation, because it facilitates interactions between tumor cells and endothelial cells (EC) (22, 23) . Secondly, it protects the tumor against immunity since it can induce apoptosis in tumor infiltrating cytotoxic leukocytes (14, 20) . This study now reports a critical role in angiogenesis, a third important pillar in tumor growth. Our results reveal a direct role of gal-1 in EC biology. We found a direct involvement of gal-1 in EC proliferation and migration in vitro and in tumor angiogenesis in vivo. While the angiogenesis-independent onset of F9 tumor growth was similar in gal-1 null and wild type mice, the angiogenesis dependent outgrowth of tumors was severely hampered in the null mice. The low microvessel density in the null mice led us to conclude that the abrogated tumor growth is caused by inefficient angiogenesis. It has been shown that gal-1 null mice have subtle neuronal abnormalities that become apparant upon challenge (24, 25) . In line with this, the effect on angiogenesis also becomes apparent by challenging the mice with a growing tumor. This corroborates with our observations in the CAM and the zebrafish, in which acute interference with gal-1 function also results in aberrant angiogenesis. Obviously, the presence of gal-1 is required for a proper response to an acute stress or pressure on EC biology and angiogenesis. It remains to be investigated whether vascular development in the null mice is indeed normal, or that subtle vascular defects do exist.
We also observed that intervening with gal-1 function results in irregular patterning of the vasculature. The abnormal vessel architecture in the CAM, the zebrafish model, and in knockout mice tumors, suggest that gal-1 is involved in vascular network formation. Recent studies have
shown that the development of both vascular and neuronal networks is regulated by the same receptor/ligand pairs, i.e. Robos/Slits, Ephrins/Eph receptors, Neuropilins/Semaphorins, and Netrins/Unc5B (26, 27) . Interestingly, for gal-1 a role in neuronal pathfinding has already been identified (28) . Furthermore, gal-1 null mice show neuronal abnormalities in adulthood (25) .
Together with the role of gal-1 in angiogenesis described here, these data strongly suggest that gal-1, as well as other members of the galectin family (galectin-3 (29, 30) ) are also involved in both neuronal and vascular development.
It has been proposed that galectins can serve as molecular targets for cancer therapy (20, (31) (32) (33) . Interestingly, we identified gal-1 as a receptor for the angiostatic peptide anginex.
Anginex has been shown to inhibit tumor growth by inhibition of tumor angiogenesis (4-6). A previous study reported that transport to the tumor vasculature is facilitated by fibronectin (34).
Our results now show that for the angiostatic activity on EC, galectin-1 is required. Anginex induced apoptosis in activated T lymphocytes (14, 20) , and (iii) prevent the execution of tumor angiogenesis (this study). This makes gal-1 an excellent target for cancer therapy.
Materials and Methods
Cell cultures
Human umbilical vein EC (HUVEC) and the human microvascular EC line HMEC were cultured as described elsewhere (5) . F9 teratocarcinoma cells (kind gift from Dr. H. Weich) were cultured in RPMI-1640 supplemented with 10% fetal bovine serum, 1% glutamin, 50 U/ml penicillin, and 50 ng/ml streptomycin.
Mouse tumor model
A total of 14 adult 129P3/J gal-1 -/-mutant mice (19) and 17 matched 129P3/J gal-1 +/+ (wild type) mice were used in this study. On day 1, animals were injected s.c. with 3x10 6 syngeneic F9 teratocarcinoma cells. On day 7, anginex treatment (10 mg/kg/day) was started in 7 wild type and 9 mutant mice by daily i.p. injections. Tumor volume and mouse weight were measured daily throughout the experiment. Animals were given water and standard chow ad libitum, and they were kept on a 12-hour light/dark cycle. All experiments were approved by the local ethical review committee.
Knockdown of galectin-1 expression in vitro
Knockdown of gal-1 expression in vitro was obtained using a gal-1 specific antisense oligodeoxynucleotide (hgal1 ODN: GTCACCGTCAGCTGCCATGT). As control, a random nonspecific antisense oligodeoxynucleotide (control ODN: TCCCTAGTGACTCTTCCC) was used. ODNs were renewed every other day.
FACS analysis
FACS analysis of gal-1 protein expression was performed on ethanol fixed HUVEC. Cells were washed in 0.1% BSA/0.01% sodium azide/PBS, incubated on ice with polyclonal rabbit antigalectin antibody (39) , and washed with PBS. Next, the cells were incubated with FITC-labeled polyclonal goat anti-rabbit Ig antibody (Dako) and washed with PBS. Five thousand events were acquired for each sample on a FACSCalibur flow cytometer (Beckton Dickinson). All experiments were performed in triplicate.
Migration, proliferation, and CAM assay
Migration, proliferation, and CAM assays were performed as described elsewhere (16) . Within each proliferation experiment, treatments were done in triplicate and all proliferation and migration experiments were performed at least three times. For the CAM, two independent experiments were performed (overall n = 13 / treatment group).
Real-time PCR
Total RNA isolation, subsequent cDNA synthesis, and real-time PCR were performed as described previously (40) with primers targeted against human gal-1 (Forward:
TGCAACAGCAAGGACGGC; Reverse: CACCTCTGCAACACTTCCA). Primers were purchased from Eurogentec and experiments were performed in triplicate.
Immunohistochemistry
Immunohistochemical staining of anginex uptake was performed on HUVEC cytospins. Cells were acetone fixed and air dried. Following incubation in 1% paraformaldehyde cells were incubated in fetal calf serum after which mouse 2D10 monoclonal anti-anginex antibody (5) was applied in 0.05% Triton X100/PBS. Following incubation with Texas Red labeled goat-anti-mouse Ig antibody, the cells were washed with PBS and mounted in Immumount (Shandon Inc.) supplemented with 1 µg/ml 4',6-diamidino-2-phenylindole (DAPI; Molecular Probes). In the negative control, incubation with the first antibody was omitted.
Doublestaining for Ki67 and CD31/34 on paraffin-embedded tissue sections was performed as previously described (41) . Tissues from normal colon, colon carcinoma, and Ewing sarcoma were obtained from the stocks of the Department of Pathology, University Hospital Maastricht. For gal-1 staining, paraffin-embedded tissue sections were dewaxed and endogenous peroxidase activity was blocked with 0.3% H 2 O 2 in methanol. Next, the slides were microwave pretreated in citric acid. After blocking with 1% BSA/PBS primary antibody was applied in 0.5%BSA/PBS.
Next, biotin-labeled secondary antibody was applied and staining was performed with the StreptABComplex/HRP kit (Dako) according the suppliers protocol. The tissue sections were counterstained with haematoxilin (Merck), dehydrated and mounted in Entellan (Merck). The same protocol was used for EC staining with the EC specific antibody 9F1 (42) . Staining for CD45+ and CD8+ cells was performed on frozen tissue sections which were fixed in acetone and air dried. Endogenous peroxidase activity was blocked with 0.3% hydrogen peroxidase/PBS and aspecific binding was blocked with 20% FCS/0.1% Tween20/PBS. Next, the primary antibody (MP33 rat anti-mouse CD45 or 53.6.27 rat anti-mouse CD8) was applied, followed by incubation with biotin labeled secondary antibody. Staining was visualized using the Vectastain ABC kit (Vector Laboratories) and subsequently, sections were counterstained with haematoxylin, dehydrated, and mounted with Entellan. Within each section, the number of positive cells was scored at 4 different locations in a blinded fashion by two different observers. Fluorescent staining of CD31 in murine tumors and subsequent scoring of vessel characteristics was performed as described before (6) .
Zebrafish experiments
For in vivo experiments, the previously described Tg(fli1:egfp) y1 zebrafish was used (17) . For whole mount blood staining, dechorionated and PTU treated embryos were incubated in 40% EtOH, 0.01M NaAc pH5.2, 2.0% H 2 O 2 , in the presence of 0.8 mg/ml o-dianisidine. Following rehydration in a graded series of EtOH/PBST the embryos were stored in 50% glycerol at 4°C.
Whole mount in situ hybridization on zebrafish embryos was carried out as previously described (44) . For VE-cadherin riboprobe synthesis we used the previously published plasmid (45) . For 
Supplementary data Results
Multiple screens against cDNA libraries of activated EC identified galectin-1 (gal-1)
as the receptor for anginex (Suppl. Table 1 ). Galectin-1 was found most frequently (15%)
while no other members of the galectin family were identified. The identification of fibronectin, of which a previous study reported that it facilitates transport of anginex to the tumor vasculature (1), confirmed the validity of the approach.
The interaction was confirmed using three approaches i) Double staining of anginex treated EC showed co-localization of anginex and gal-1 (Suppl. 1E ).
The in vivo role of gal-1 in angiogenesis was studied in the chick chorioallantoic membrane (CAM). Treatment of the CAM with a rabbit polyclonal anti-gal-1 antibody induced a significant inhibition of microvessel density, similar as previously published for anginex albeit less pronounced (Suppl. Fig. 2A) . Interestingly, treatment caused tortuous and irregular growth of the vessels, suggesting a defect in vascular guidance (Suppl. Fig. 2B ).
In the tumors of gal-1 null mice, several parameters of vessel architecture were decreased, indicative of a less comples and less developed vasculature (Suppl. Table 2 ).
Galectin-1 has been shown to mediate apoptosis in activated T cells, which could also contribute positively to tumor growth (2) . To determine whether this also occurred in our tumor model we quantified the amount of peripheral blood leukocytes and the presence of CD45+ and CD8+ cells in the tumors. In our teratocarcinoma model there was no significant difference in these parameters between gal-1+/+ and gal-1-/-animals (Suppl. Fig. 3 ) which strongly suggests that, in this model, impaired tumor progression in gal-1 null mice largely results from decreased angiogenesis.
In addition, anginex treatment did not significantly affect the number of infiltrating CD45+ or CD8+ cells in the tumors of both the wild type and null mice (Suppl. Fig. 4 ).
Materials and Methods
Yeast two-hybrid screening
Yeast two-hybrid screening was performed using the MATCHMAKER GAL4 Two-Hybrid System 3 (Clontech) according to the manufacturers instructions. In short, the artificial anginex gene (3) was PCR amplified and cloned into bait vector pGBKT7 in frame with the GAL4 DNA binding domain (pBD-Ax). The construct was tested for absence of transcriptional activation and toxicity. Subsequently, yeast AH109 cells were co-transformed with pBD-Ax, SmaI-linearized prey vector (pGADT7), and a cDNA library which was generated from activated HUVEC mRNA. Following growth on media plates selective for reporter gene activation, prey plasmids from positive yeast colonies were isolated using CHROMA SPIN-1000 columns (Clontech), shuttled into E.Coli, and sequenced using an automatic DNA-sequencer (AbiPrism377, Applied Biosystems). Confirmation of interaction was performed by targeted transformation of the specific constructs using the small-scale yeast transformation protocol as described in the yeast protocol handbook (Clontech).
Surface Plasmon Resonance
Real-time monitoring of molecular interactions was performed at 25°C using the BIAcore 1000 biosensor system (BiaCore) according to the manufacturer's instructions. In short, recombinant human galectin-1 (4) was immobilized to a CM5 sensor chip (BiaCore) via primary amine groups using the Amine Coupling Kit (BiaCore). For interaction analysis, 20
µl sample was diluted to various concentrations in HBS-EP (Biacore) and was injected using the KINJECT command at a flow rate of 30 µl/minute after which the flow cells were regenerated by injection of 20 µl regeneration buffer (10 mM glycine-HCl, pH 2.0).
Association-rate (k a ) and dissociation-rate (k d ) constants were obtained by analysis of the sensograms using the Biaevaluation software, version 3.2. All measurements were performed at least in duplicate at all concentrations and the experiment was performed in duplo.
NMR Spectroscopy
For NMR measurements, 5 mg of recombinant human galectin-1 (4) was dissolved in 600 μl of 10mM potassium phosphate buffer made with 95%/5% H 2 O/D 2 O at pH 5.2. Freeze-dried anginex was dissolved in 10 μl of the same buffer and added to the galectin sample at the molar ratio of 1:2 (anginex:galectin). 2D-homonuclear TOCSY spectra (5) with WATERGATE for water suppression, were acquired on a Varian UNITY Plus-600 NMR spectrometer at 30°C. 2048 complex data points along t2 and 256 increments along t1
dimensions over a spectral width of 9000 Hz, were collected. A mixing time of 50 ms was used. Data were processed using a Gaussian window function and the program NMRPipe (6).
Electron Microscopy
For electron microscopy, HUVEC were grown on gelatin coated and glutaraldehyde fixed thermanox cover slips in normal HUVEC culture medium supplemented with 75 µM anginex.
Subsequently, cells were fixed with 1% paraformaldehyde, and localization of anginex by jet freezing and freeze substitution was performed as described previously (7), using polyclonal rabbit anti-anginex antibody in combination with immunogold labeled goat anti-rabbit antibody (Aurion).
